Endoscopic transpapillary gallbladder drainage for acute cholecystitis is feasible for patients receiving antithrombotic therapy. Issue 7 (1st April 2020)

• Record Type: Journal Article
• Authors: Sagami, Ryota; Hayasaka, Kenji; Ujihara, Tetsuro; Nakahara, Ryotaro; Murakami, Daisuke; Iwaki, Tomoyuki; Suehiro, Satoshi; Katsuyama, Yasushi; Harada, Hideaki; Nishikiori, Hidefumi; Murakami, Kazunari; Amano, Yuji
• Is Part Of: Digestive endoscopy. Volume 32:Issue 7(2020)
• Page Start: 1092
• Page End: 1099
• Publication Date: 2020-04-01
• Subjects: acute cholecystitis -- antithrombotic therapy -- endoscopic retrograde cholangiopancreatography -- endoscopic transpapillary gallbladder drainage -- percutaneous transhepatic gallbladder drainage; Digestive organs -- Diseases -- Periodicals; Digestive organs -- Diseases -- Diagnosis -- Periodicals; Endoscopy -- Periodicals; Digestive System Diseases -- diagnosis -- Periodicals; Digestive System Diseases -- therapy -- Periodicals; Endoscopy -- Periodicals; 616.3
• DOI: 10.1111/den.13650
• Languages: English
• ISSNs: 0915-5635

Abstract

Abstract : Objectives: Patients with acute cholecystitis receiving antithrombotic therapy (ATT) have an increased risk of bleeding complications during surgery and percutaneous drainage. Endoscopic transpapillary gallbladder drainage (ETGBD) is recommended for such cases; however, evidence is limited. To investigate this issue further, we performed a retrospective multicenter study. Methods: One hundred thirty patients with acute cholecystitis who underwent ETGBD were enrolled. They were divided into an ATT group (continuation of ATT on the day of the procedure and/or heparin substitution) and a Non‐ATT group (discontinuation or no use of ATT). The primary outcome was bleeding complication rate, and the secondary outcomes were technical success rate, clinical success rate and total complication rate. Results: Eighty‐three patients were enrolled in the ATT group, and 47 were enrolled in the Non‐ATT group. In the ATT group, 42.2% continued multi‐agent ATT. No bleeding complications occurred in either group. There were no significant differences between the ATT and Non‐ATT groups in the technical success rate (84.3% vs 89.4%, P = 0.426 respectively) or the clinical success rate (97.1% vs 100%, P = 0.259, respectively). The overall early complication rate was 3.1% (4/130): mild pancreatitis ( n = 3) and cholangitis ( n = 1). Stent dysfunction was found in 10.9% of patients (at 196 days on average), and the 12‐month stent patency rate was 69.0%. Conclusions: No significant difference was found in the bleeding complication rate between ETGBD with and without ATT. ETGBD may be an ideal drainage method for patients with acute cholecystitis receiving ATT.